Sanofi and Seagen Inc. (Nasdaq:SGEN) announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology.
Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
March 19, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022